Free Trial
NYSE:RDY

Dr. Reddy's Laboratories (RDY) Stock Price, News & Analysis

Dr. Reddy's Laboratories logo
$73.89
-1.26 (-1.68%)
(As of 10:51 AM ET)

About Dr. Reddy's Laboratories Stock (NYSE:RDY)

Key Stats

Today's Range
$73.74
$75.15
50-Day Range
$75.20
$84.21
52-Week Range
$63.72
$84.46
Volume
14,884 shs
Average Volume
209,713 shs
Market Capitalization
$12.33 billion
P/E Ratio
18.47
Dividend Yield
0.54%
Price Target
$87.00
Consensus Rating
Hold

Company Overview

Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company's Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business. The PSAI segment manufactures and markets active pharmaceutical ingredients and intermediates, which are principal ingredients for finished pharmaceutical products. This segment also provides contract research services; and manufactures and sells active pharmaceutical ingredients and steroids in accordance with the specific customer requirements. The Others segment engages in developing therapies in the fields of oncology and inflammation; research and development of differentiated formulations; and provides digital healthcare and information technology enabled business support services. The company offers its products for various therapeutic categories primarily include gastro-intestinal, cardiovascular, anti-diabetic, dermatology, oncology, respiratory, stomatology, urology, and nephrology. Dr. Reddy's Laboratories Limited was incorporated in 1984 and is headquartered in Hyderabad, India.

Dr. Reddy's Laboratories Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks
35th Percentile Overall Score

RDY MarketRank™: 

Dr. Reddy's Laboratories scored higher than 35% of companies evaluated by MarketBeat, and ranked 812th out of 999 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Dr. Reddy's Laboratories has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on 1 buy rating, no hold ratings, and 1 sell rating.

  • Amount of Analyst Coverage

    Dr. Reddy's Laboratories has received no research coverage in the past 90 days.

  • Read more about Dr. Reddy's Laboratories' stock forecast and price target.
  • Earnings Growth

    Earnings for Dr. Reddy's Laboratories are expected to grow by 0.49% in the coming year, from $4.11 to $4.13 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Dr. Reddy's Laboratories is 18.80, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 134.79.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Dr. Reddy's Laboratories is 18.80, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 137.39.

  • Price to Earnings Growth Ratio

    Dr. Reddy's Laboratories has a PEG Ratio of 1.73. PEG Ratios above 1 indicate that a company could be overvalued.

  • Price to Book Value per Share Ratio

    Dr. Reddy's Laboratories has a P/B Ratio of 3.73. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about Dr. Reddy's Laboratories' valuation and earnings.
  • Percentage of Shares Shorted

    1.32% of the outstanding shares of Dr. Reddy's Laboratories have been sold short.
  • Short Interest Ratio / Days to Cover

    Dr. Reddy's Laboratories has a short interest ratio ("days to cover") of 12.3, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Dr. Reddy's Laboratories has recently increased by 2.33%, indicating that investor sentiment is decreasing.
  • Dividend Yield

    Dr. Reddy's Laboratories has a dividend yield of 0.52%, which is in the bottom 25% of all stocks that pay dividends.

  • Dividend Growth

    Dr. Reddy's Laboratories does not have a long track record of dividend growth.

  • Dividend Coverage

    The dividend payout ratio of Dr. Reddy's Laboratories is 9.93%. This payout ratio is at a healthy, sustainable level, below 75%.

  • Dividend Sustainability

    Based on earnings estimates, Dr. Reddy's Laboratories will have a dividend payout ratio of 9.69% next year. This indicates that Dr. Reddy's Laboratories will be able to sustain or increase its dividend.

  • Read more about Dr. Reddy's Laboratories' dividend.
  • Percentage of Shares Shorted

    1.32% of the outstanding shares of Dr. Reddy's Laboratories have been sold short.
  • Short Interest Ratio / Days to Cover

    Dr. Reddy's Laboratories has a short interest ratio ("days to cover") of 12.3, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Dr. Reddy's Laboratories has recently increased by 2.33%, indicating that investor sentiment is decreasing.
  • News Sentiment

    Dr. Reddy's Laboratories has a news sentiment score of 0.22. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.67 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 7 news articles for Dr. Reddy's Laboratories this week, compared to 3 articles on an average week.
  • Search Interest

    3 people have searched for RDY on MarketBeat in the last 30 days.
  • MarketBeat Follows

    2 people have added Dr. Reddy's Laboratories to their MarketBeat watchlist in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Dr. Reddy's Laboratories insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 2.00% of the stock of Dr. Reddy's Laboratories is held by insiders.

  • Percentage Held by Institutions

    Only 14.02% of the stock of Dr. Reddy's Laboratories is held by institutions.

  • Read more about Dr. Reddy's Laboratories' insider trading history.
Receive RDY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Dr. Reddy's Laboratories and its competitors with MarketBeat's FREE daily newsletter.

RDY Stock News Headlines

Dr. Reddy’s Launches Groundbreaking Drug in India
The real reason Elon is fully endorsing Trump
Elon Musk is one of mankind’s greatest innovators. But for all his visionary prowess and contributions to humanity, there is a war being waged on Elon Musk. This war has nothing to do with X, Elon’s stance on immigration or his support for Donald Trump.
Journey Medical announces presentation of DFD-29 data
See More Headlines

RDY Stock Analysis - Frequently Asked Questions

Dr. Reddy's Laboratories' stock was trading at $69.58 at the beginning of the year. Since then, RDY stock has increased by 8.1% and is now trading at $75.20.
View the best growth stocks for 2024 here
.

Dr. Reddy's Laboratories Limited (NYSE:RDY) released its earnings results on Wednesday, January, 31st. The company reported $0.99 EPS for the quarter, beating analysts' consensus estimates of $0.88 by $0.11. The business had revenue of $867 million for the quarter, compared to analyst estimates of $827.81 million. Dr. Reddy's Laboratories had a trailing twelve-month return on equity of 20.32% and a net margin of 19.28%.

Dr. Reddy's Laboratories's stock split on Tuesday, November 5th 2024. The 5-1 split was announced on Thursday, September 12th 2024. The newly minted shares will be issued to shareholders after the market closes on Monday, November 4th 2024. An investor that had 100 shares of stock prior to the split would have 500 shares after the split.

Dr. Reddy's Laboratories' top institutional investors include Robeco Institutional Asset Management B.V. (1.24%), Allspring Global Investments Holdings LLC (0.06%), Creative Planning (0.06%) and Artemis Investment Management LLP (0.04%).

Shares of RDY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that Dr. Reddy's Laboratories investors own include Siemens Aktiengesellschaft (SIEGY), Meta Platforms (META), NVIDIA (NVDA), Advanced Micro Devices (AMD), Netflix (NFLX), Tesla (TSLA) and JPMorgan Chase & Co. (JPM).

Company Calendar

Last Earnings
1/31/2024
Today
10/30/2024
Next Earnings (Estimated)
11/01/2024
Fiscal Year End
3/31/2025

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Employees
27,048
Year Founded
1984

Price Target and Rating

Average Stock Price Target
$87.00
High Stock Price Target
$87.00
Low Stock Price Target
$87.00
Potential Upside/Downside
+15.7%
Consensus Rating
Hold
Rating Score (0-4)
2.00
Research Coverage
2 Analysts

Profitability

Net Income
$668 million
Pretax Margin
24.88%

Debt

Sales & Book Value

Annual Sales
$288.51 billion
Cash Flow
$4.84 per share
Book Value
$20.17 per share

Miscellaneous

Free Float
163,601,000
Market Cap
$12.55 billion
Optionable
Optionable
Beta
0.55

Social Links

20 Stocks to Sell Now Cover

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report

This page (NYSE:RDY) was last updated on 10/30/2024 by MarketBeat.com Staff
From Our Partners